A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study için istatistikler
Toplam ziyaret
| views | |
|---|---|
| A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Ocak 2024 | 0 |
| Şubat 2024 | 0 |
| Mart 2024 | 0 |
| Nisan 2024 | 0 |
| Mayıs 2024 | 0 |
| Haziran 2024 | 0 |
| Temmuz 2024 | 0 |
